An Open-label study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Ibrutinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Pharmacyclics
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2018 Planned End Date changed from 1 Feb 2020 to 1 Jul 2019.
- 25 Jul 2018 This trial has been Completed in Poland according to European Clinical Trials Database record.